Cerep

Cerep is a prominent contract research organization (CRO) and biotechnology company that provides high-throughput screening and in vitro pharmacology services to the global pharmaceutical industry. Founded in 1989 and headquartered in France, the company is best known for its BioPrint platform, a large-scale database used to predict the clinical efficacy and safety of drug candidates. Cerep's services include ADME-Tox profiling, lead optimization, and custom assay development across various target classes such as G protein-coupled receptors, kinases, and ion channels. In 2013, the company was acquired by Eurofins Scientific, integrating its expertise into the Eurofins Discovery portfolio. Today, it continues to support drug discovery programs by providing critical data for candidate selection and risk assessment.